Leif Johansson - Chairman, AstraZeneca

Chairman’s Statement

“As expected, our financial performance in 2013 reflected the ongoing impact of the loss of exclusivity for several key brands, with revenue down 6% to $25,711 million.”
Read the statement
Pascal Soriot - CEO, AstraZeneca

Chief Executive
Officer’s Review

“I am pleased with the momentum we built in 2013 against our strategic priorities, particularly our objective of achieving scientific leadership.”
Read the review

At a glance

Employees icon 51,500*
employees worldwide
 
Research and development icon 9,000*
employees work in R&D
 
sales and marketing icon 29,600*
employees work in Sales and Marketing
supply and manufacturing icon 8,700*
employees work in Supply and Manufacturing
Our Group at a glance

*All figures are approximate.

Financial summary

  • $25.7 billion
    Sales down 6% at CER to $25,711 million ($27,973 million in 2012)
    $8.4 billion
    Core operating profit down 23% at CER to $8,390 million ($11,159* million in 2012)
    $5.05
    Core EPS for the full year decreased by 23% at CER to $5.05 ($6.83^ in 2012)
  • $3.0 billion
    Net cash shareholder distributions decreased by 49% to $2,979 million, partly as a result of the cessation of the share repurchase programme ($5,871 million net cash shareholder distributions including $2,206 million net share repurchases in 2012)
    $3.7 billion
    Reported operating profit down 51% at CER to $3,712 million ($8,148 million in 2012)
    $2.04
    Reported EPS for the full year decreased by 55% at CER to $2.04 ($4.95 in 2012)
Our financial summary
*
Restated for new Core definition.
^
Restated for new Core definition and adoption of IAS 19 (2011).
Restated on adoption of IAS 19 (2011).

Life-cycle of a medicine

AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from research, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives.

Find out more

How we add value

Our Business model demonstrates how we apply our resources to our chosen therapy areas across the whole life-cycle of a medicine to help deliver our strategic priorities and add value.

Find out more